NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 38.0% and is now trading at $48.55. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences.

Pacira Biosciences Inc (NASDAQ:PCRX) announced its quarterly earnings results on Thursday, May, 7th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.30 by $0.23. The firm had revenue of $105.68 million for the quarter, compared to analyst estimates of $101.64 million. Pacira Biosciences had a positive return on equity of 13.89% and a negative net margin of 0.02%. The firm's revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.22 EPS. View Pacira Biosciences' earnings history.

15 brokerages have issued 1 year target prices for Pacira Biosciences' shares. Their forecasts range from $41.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $54.50 in the next twelve months. This suggests a possible upside of 12.3% from the stock's current price. View analysts' price targets for Pacira Biosciences.

News coverage about PCRX stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pacira Biosciences earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPacira Biosciences.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX).

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.35%), State Street Corp (3.33%), Spyglass Capital Management LLC (2.83%), Clearbridge Investments LLC (2.67%), Frontier Capital Management Co. LLC (2.57%) and Schroder Investment Management Group (1.94%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Investments LP, Schroder Investment Management Group, Nuveen Asset Management LLC, Maverick Capital Ltd., Maverick Capital Ltd., Two Sigma Advisers LP, and UBS Group AG. Company insiders that have sold Pacira Biosciences company stock in the last year include David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, and Lauren Bullaro Riker. View insider buying and selling activity for Pacira Biosciences.

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Spyglass Capital Management LLC, Loomis Sayles & Co. L P, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, State Street Corp, Russell Investments Group Ltd., Mesirow Financial Investment Management Equity Management, and Granahan Investment Management Inc. MA. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $48.55.

Pacira Biosciences has a market capitalization of $2.04 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.

The official website for Pacira Biosciences is www.pacira.com.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]